News

Basic research: Inhibition of epigenetic control enzymes in immune cells as a potential new starting point in cancer immunotherapy

30 Millionen Investment für Pharmastandort

Millioneninvestition in Pharmastandort Österreich

LEPTON Pharmaceuticals LTD and TAmiRNA GmbH enhance their collaboration

Austrian Life Science Day 2024 mit Schwerpunkt zum Thema Gesundheitsdaten

OGNT: World Prostate Cancer Day

Roche: „Jetzt reden wir!“ Frauen fordern Umbruch im Gesundheitssystem

University Vienna: Uptake of tire wear additives by vegetables grown for human consumption

VALANX Biotech Announces Promising Results in First In-Vivo Study of Novel Protein Conjugate Therapy

MedUni Vienna: Prostate cancer: Protein identified to reduce tumour growth

TMW: Innovationen aus Medizintechnik und Life Sciences

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

KLU: New Role of Tumor Suppressor STAT3β Discovered in Leukemia

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

MedUni Vienna: Heart: New heart valve prosthesis enables broader applicability

AstraZeneca Österreich präsentiert neue Initiative "Frauen im Fokus" zur Förderung von Gender Equality in der Medizin

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

LISAvienna: wings4innovation advances the search for a new therapeutic approach to the treatment of osteoarthritis

LISAvienna: wings4innovation advances the search for a new therapeutic approach to the treatment of osteoarthritis

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine